NeuroSense Therapeutics Ltd. (NRSN) is a late-stage biotherapeutics company engaged in the discovery and development of therapeutics for patients with neurodegenerative diseases. The company believes that Amyotrophic Lateral Sclerosis, Alzheimer’s, and, Parkinson’s disease represent significant unmet medical needs nowadays. One of the pipeline candidates of the company is PrimeC in Phase 2 clinical studies for ALS. The company is proceeding with Alzheimer’s and Parkinson’s disease programs and is aiming to start clinical trials for them in the first half of 2023.
The price of NRSN stock during the regular trading on February 25, 2022, was $1.51 with a gain of 7.86%. At last check in the premarket on February 28, 2022, the stock rocketed further by 35.76%.
NRSN: Events and Happenings
On February 24, 2022, NRSN updated its Executive management will present at the Annual Meeting of American Society for Experimental Neurotherapeutics 2022 from February 28-March 3, 2022, on the topic titled “Breaking the Paradigm – PrimeC as a Novel Approach to ALS Therapy”. On February 22, 2022, NRSN reported its management’s participation at the Virtual Aegis Capital Corp. Conference on February 25th.
On January 31, 2022, NRSN announced the company’s CEO, Alon Ben-Noon presented at the BIO CEO & Investor Conference on February 15, 2022. On January 27, 2022, NRSN informed the initiation of the collaborative biomarker stage 3 study with Massachusetts General Hospital. On January 4, 2022, NRSN reported four research-oriented conferences being attended by its top management. These conferences include
- 16thInternational Conference on Alzheimer’s & Parkinson’s to be held in March 2022 where the company’s Phase 2 clinical trial outcomes have been acknowledged to present.
- The Annual ALS ONE Research Symposium held in the fourth quarter of 2021.
- The ALS/MND Symposium 2021 held Q4 2021, and
- The Israeli Neurological Association Annual Meeting held Q4 2021.
On December 13, 2021, NRSN reported the closure of its preliminary public offering of 2,000,000 units on the NASDAQ. Each unit consists of one ordinary share and a warrant at an exercise price of $6.00 per share, at the preliminary price offered to the public for $6.00 per unit. Additionally, the company had also granted a purchase option of up to 300,000 additional ordinary shares and 300,000 additional warrants at the initial public offering price. The net proceeds from the offering were up to $12 million.
Conclusion
NRSN shares and warrants started trading on the NASDAQ on December 9, 2021. The company’s stock is 42% down the year-to-date period. Its recent premarket stock rise is possibly the effect of its clinical outcome’s presentation at the ASENT Annual Meeting 2022. The financial statement of the company is not available on its official website hence the key financial figures are not discussed.
